Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Submitted by
admin
on February 6, 2010 - 12:22pm
Source:
Yahoo/MarketWire
News Tags:
Keryx
perifosine
colorectal cancer
Headline:
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Do Not Allow Advertisers to Use My Personal information
